Novartis Projects OTC Return By Summer

By Dan Schiff / Email the Author / Health News Daily Jan. 26, 2012
Today's Stories / Word Count: 433 / Article # 29120126002

Executive Summary

Novartis’ 2012 guidance conservatively assumes the offline OTC facility in Lincoln, Neb., will return to production by mid-year, CEO Joseph Jimenez says. The firm halted shipments of Excedrin and other OTCs from Lincoln in December, and consumer health sales fell 7.3% in the fourth quarter.

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 433-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

Offers & Events

Topics Covered in this Article

Click a keyword for related articles.
General Topics
Finances
Drug recalls
Subjects
Financial Strategies
Emerging Markets
Manufacturing
Industries
Consumer Products
Otc Drugs
Regions
North America
United States
Europe
Companies
Novartis AG
Novartis Consumer Health Inc.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Novartis Projects OTC Return By Summer

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to Health News Daily will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel